Chopra Daveen 4

What Happened

• Daveen Chopra, CVP, TMTT & Surgical at Edwards Lifesciences (EW), had 13,583 performance-based shares convert/vest on May 11, 2026 (reported 5/12/2026). The vesting shares were valued at $79.96 each (market price used for withholding), for a gross value of about $1.086M. To cover tax withholding, 7,538 shares were surrendered (disposed) at $79.96 for $602,738, leaving a net issuance of 6,045 shares worth roughly $483,358 to the reporting person.
• Transaction codes: M = exercise/conversion of derivative (performance rights/units), F = shares withheld to satisfy tax liability.

Key Details

• Transaction date: May 11, 2026; filing date: May 12, 2026 (timely).
• Price used for withholding: $79.96 per share.
• Shares vesting (acquired): 13,583; shares withheld for taxes (disposed): 7,538; net shares delivered: 6,045.
• Gross value of vested shares ≈ $1,086,097; tax withholding value = $602,738; net value delivered ≈ $483,358.
• Footnote F1: These were performance-based restricted stock units granted May 11, 2023; Compensation Committee certified 167.70% of target vested as of May 11, 2026. Footnote F2: Performance rights expire May 10, 2030.
• Shares owned after the transaction are not specified in the Form 4 (filing only reports the change).

Context

• This was not an open-market sale by the insider but a routine net settlement/tax-withholding on vesting of performance awards (common practice). The F-code disposition reflects shares surrendered to satisfy tax withholding, not a directional sale signal.
• For retail investors: vesting of performance awards increases insider ownership but withheld shares reduce the net issuance; this filing documents ownership change, not a market trade.